Jim Thomas is a founding partner and CEO at Just Biotherapeutics, Inc. Jim is leveraging his extensive experience in biotechnology and scientific leadership to deliver the mission of Just. Over the course of his career, Jim’s passion has been to provide vital medicines to patients, and his vision for Just expands this to include patients worldwide.
Previously, Jim served as vice president of Process and Product Development within the Translational Sciences R&D organization at Amgen. In this role, he led the development and application of all process, analytical and formulation technologies used to manufacture both clinical and commercial large molecule products. Jim began his industrial career at Genentech in 1983 as a scientist in Cell Culture R&D before joining the department of Molecular Biology at Immunex Corporation in 1990. At Immunex, Jim initiated the effort to produce recombinant proteins using mammalian cells as the host cell system. As Director of Cell Sciences and then Vice President of Process Sciences, he oversaw investment in technologies that became foundational for large-scale manufacturing. Over the course of his career, Jim as contributed to the advancement of many important therapeutics including Activase®, Vectibix®, Enbrel®, Prolia®/Xgeva® and Repatha™, as well as numerous biosimilar programs. Jim has built teams, departments and functions passionate about creating and using innovative technologies to deliver to the needs of patients.
Jim received his Ph.D. from Purdue University and completed a post-doctoral fellowship at MIT in biochemistry, nutrition and cell physiology.